SlideShare a Scribd company logo
Traditional statistical methods for evaluating prediction models are uninformative: towards a decision analytic approach ,[object Object],[object Object],[object Object]
The Kattan challenge A clinician comes to you  with two models (or tests) and wants to know which to use. What statistical method do you use to help answer the clinician?
Traditional biostatistical metrics   Sensitivity Specificity PPV NPV LR+ LR- AUC (Youden) Brier (mean squared error) % Free PSA < 20% 91% 40% 35% 92% 1.52 0.23 0.65 0.47 hK2 > 75 pg / ml 51% 78% 45% 82% 2.32 0.63 0.64 0.29
Which test is best? ,[object Object],[object Object]
Conclusion about traditional metrics ,[object Object],[object Object],How do we guide the clinician?
Prostate cancer High risk (10%) Low Risk (90%)
Prostate cancer Use of the model to determine treatment would avoid 47 unnecessary treatments at the expense of failing to treat 45 patients who do require treatment.
Discrimination ,[object Object],[object Object],[object Object]
Discrimination rules! ,[object Object],[object Object]
From the literature ,[object Object],[object Object]
Discrimination? So what? ,[object Object],[object Object],[object Object],[object Object]
Discrimination? So what? ,[object Object],[object Object],[object Object],[object Object]
Extremely bad models can have extremely good discrimination ,[object Object],[object Object],[object Object],[object Object]
Calibration ,[object Object],[object Object]
Calibration plot
Problem with calibration ,[object Object],[object Object],[object Object]
Incorporating clinical consequences ,[object Object],[object Object],[object Object],[object Object]
What is the “depends” parameter? ,[object Object],[object Object],[object Object],[object Object]
Intuitively ,[object Object],[object Object],[object Object]
Clinical net benefit ,[object Object]
Application to models with a continuous endpoint 1. Select a  p t   2. Positive test defined as   3. Calculate “Clinical Net Benefit” as:
Kallikrein panel: weight false positives by 20% ÷ (1 – 20%) Cancers found Unecessary Biopsies Net benefit Biopsy all men with elevated PSA   277 723 277 - 723 ÷ 4 96.25 Biopsy if  risk ≥ 20% on panel 211 276 211 - 276 ÷ 4 142
Net benefit has simple clinical interpretation ,[object Object],[object Object]
Net benefit has simple clinical interpretation ,[object Object],[object Object],[object Object],[object Object],[object Object]
Decision curve analysis 4. Vary  p t   over an appropriate range  Vickers & Elkin Med Decis Making 2006;26:565–574 1. Select a  p t   2. Positive test defined as   3. Calculate “Clinical Net Benefit” as:
Decision curve analysis
Gallina vs. Partin ,[object Object],[object Object],P=0.02
Decision curve analysis
 
 
Statistical analysis vs. decision analysis Traditional statistical analysis Traditional decision analysis Mathematics Simple Can be complex Additional data Not required Patient preferences, costs or effectiveness Endpoints Binary or  continuous Continuous endpoints problematic Assess clinical value? No Yes
Statistical analysis vs. decision analysis Traditional statistical analysis Traditional decision analysis Decision curve analysis Mathematics Simple Can be complex Simple Additional data Not required Patient preferences, costs or effectiveness Informal, general estimates Endpoints Binary or  continuous Continuous endpoints problematic Binary or continuous Assess clinical value? No Yes Yes
Decision curve analysis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

More Related Content

What's hot

Sample size calculation
Sample size calculationSample size calculation
Sample size calculation
Ramachandra Barik
 
Bayesian clinical test
Bayesian clinical testBayesian clinical test
Bayesian clinical test
Gaetan Lion
 
Practical Methods To Overcome Sample Size Challenges
Practical Methods To Overcome Sample Size ChallengesPractical Methods To Overcome Sample Size Challenges
Practical Methods To Overcome Sample Size Challenges
nQuery
 
Combination of informative biomarkers in small pilot studies and estimation ...
Combination of informative  biomarkers in small pilot studies and estimation ...Combination of informative  biomarkers in small pilot studies and estimation ...
Combination of informative biomarkers in small pilot studies and estimation ...
LEGATO project
 
Minimizing Risk In Phase II and III Sample Size Calculation
Minimizing Risk In Phase II and III Sample Size CalculationMinimizing Risk In Phase II and III Sample Size Calculation
Minimizing Risk In Phase II and III Sample Size Calculation
nQuery
 
.Screening tests
.Screening tests.Screening tests
.Screening tests
MtMt37
 
Data mining for diabetes readmission
Data mining for diabetes readmissionData mining for diabetes readmission
Data mining for diabetes readmission
Yi Chun (Nancy) Chien
 
Peds journal club 2 -diagnostic test
Peds journal club 2 -diagnostic testPeds journal club 2 -diagnostic test
Peds journal club 2 -diagnostic testcoolboy101pk
 
Describing the performance of a diagnostic test
Describing the performance of a diagnostic testDescribing the performance of a diagnostic test
Describing the performance of a diagnostic test
Amany El-seoud
 
POC Breast 1 | 2007 - Adjuvant Endocrine Therapy
POC Breast 1 | 2007 -  	Adjuvant Endocrine TherapyPOC Breast 1 | 2007 -  	Adjuvant Endocrine Therapy
POC Breast 1 | 2007 - Adjuvant Endocrine Therapyrtp
 
Machine learning in medicine: calm down
Machine learning in medicine: calm downMachine learning in medicine: calm down
Machine learning in medicine: calm down
BenVanCalster
 
Big Data Analytics for Healthcare
Big Data Analytics for HealthcareBig Data Analytics for Healthcare
Big Data Analytics for Healthcare
Chandan Reddy
 
Sample size calculation in medical research
Sample size calculation in medical researchSample size calculation in medical research
Sample size calculation in medical research
Kannan Iyanar
 
Day 1 (Lecture 3): Predictive Analytics in Healthcare
Day 1 (Lecture 3): Predictive Analytics in HealthcareDay 1 (Lecture 3): Predictive Analytics in Healthcare
Day 1 (Lecture 3): Predictive Analytics in Healthcare
Aseda Owusua Addai-Deseh
 
7. evaluation of diagnostic test
7. evaluation of diagnostic test7. evaluation of diagnostic test
7. evaluation of diagnostic test
Ashok Kulkarni
 
Biomarker discovery and validation
Biomarker discovery and validationBiomarker discovery and validation
Biomarker discovery and validationWinton Gibbons
 
Sample size
Sample sizeSample size
Sample sizezubis
 
Make clinical prediction models great again
Make clinical prediction models great againMake clinical prediction models great again
Make clinical prediction models great again
BenVanCalster
 
Choosing Regression Models
Choosing Regression ModelsChoosing Regression Models
Choosing Regression Models
Stephen Senn
 
Predictive Medicine
Predictive Medicine Predictive Medicine
Predictive Medicine
Khuloud Edwards
 

What's hot (20)

Sample size calculation
Sample size calculationSample size calculation
Sample size calculation
 
Bayesian clinical test
Bayesian clinical testBayesian clinical test
Bayesian clinical test
 
Practical Methods To Overcome Sample Size Challenges
Practical Methods To Overcome Sample Size ChallengesPractical Methods To Overcome Sample Size Challenges
Practical Methods To Overcome Sample Size Challenges
 
Combination of informative biomarkers in small pilot studies and estimation ...
Combination of informative  biomarkers in small pilot studies and estimation ...Combination of informative  biomarkers in small pilot studies and estimation ...
Combination of informative biomarkers in small pilot studies and estimation ...
 
Minimizing Risk In Phase II and III Sample Size Calculation
Minimizing Risk In Phase II and III Sample Size CalculationMinimizing Risk In Phase II and III Sample Size Calculation
Minimizing Risk In Phase II and III Sample Size Calculation
 
.Screening tests
.Screening tests.Screening tests
.Screening tests
 
Data mining for diabetes readmission
Data mining for diabetes readmissionData mining for diabetes readmission
Data mining for diabetes readmission
 
Peds journal club 2 -diagnostic test
Peds journal club 2 -diagnostic testPeds journal club 2 -diagnostic test
Peds journal club 2 -diagnostic test
 
Describing the performance of a diagnostic test
Describing the performance of a diagnostic testDescribing the performance of a diagnostic test
Describing the performance of a diagnostic test
 
POC Breast 1 | 2007 - Adjuvant Endocrine Therapy
POC Breast 1 | 2007 -  	Adjuvant Endocrine TherapyPOC Breast 1 | 2007 -  	Adjuvant Endocrine Therapy
POC Breast 1 | 2007 - Adjuvant Endocrine Therapy
 
Machine learning in medicine: calm down
Machine learning in medicine: calm downMachine learning in medicine: calm down
Machine learning in medicine: calm down
 
Big Data Analytics for Healthcare
Big Data Analytics for HealthcareBig Data Analytics for Healthcare
Big Data Analytics for Healthcare
 
Sample size calculation in medical research
Sample size calculation in medical researchSample size calculation in medical research
Sample size calculation in medical research
 
Day 1 (Lecture 3): Predictive Analytics in Healthcare
Day 1 (Lecture 3): Predictive Analytics in HealthcareDay 1 (Lecture 3): Predictive Analytics in Healthcare
Day 1 (Lecture 3): Predictive Analytics in Healthcare
 
7. evaluation of diagnostic test
7. evaluation of diagnostic test7. evaluation of diagnostic test
7. evaluation of diagnostic test
 
Biomarker discovery and validation
Biomarker discovery and validationBiomarker discovery and validation
Biomarker discovery and validation
 
Sample size
Sample sizeSample size
Sample size
 
Make clinical prediction models great again
Make clinical prediction models great againMake clinical prediction models great again
Make clinical prediction models great again
 
Choosing Regression Models
Choosing Regression ModelsChoosing Regression Models
Choosing Regression Models
 
Predictive Medicine
Predictive Medicine Predictive Medicine
Predictive Medicine
 

Viewers also liked

Политический капитал оппозиционного политика
Политический капитал оппозиционного политикаПолитический капитал оппозиционного политика
Политический капитал оппозиционного политика
Ivan Zvyagin
 
Slide 1
Slide 1Slide 1
Slide 1
pepanh
 
Installing nagios core_from_source
Installing nagios core_from_sourceInstalling nagios core_from_source
Installing nagios core_from_source
laonap166
 
Cellulair imuunrespons
Cellulair imuunresponsCellulair imuunrespons
Cellulair imuunrespons
Nawid Akbari
 
Tony kelly
Tony kellyTony kelly
Tony kelly
Investnet
 
Securities and Exchange Commission Filings - Reynolds Week 2011
Securities and Exchange Commission Filings - Reynolds Week 2011Securities and Exchange Commission Filings - Reynolds Week 2011
Securities and Exchange Commission Filings - Reynolds Week 2011
Reynolds Center for Business Journalism
 
Tabernakel1
Tabernakel1Tabernakel1
Tabernakel1
dgorter
 
Calendario student card 2017
Calendario student card 2017Calendario student card 2017
Calendario student card 2017
Connor Yons
 
Data envelopment analysis
Data envelopment analysisData envelopment analysis
Data envelopment analysisAjit Kumar Ray
 
Target audience guidance
Target audience guidanceTarget audience guidance
Target audience guidance
hughes82
 
Reken maar 6
Reken maar 6Reken maar 6
Reken maar 6
goedbericht
 
Paulus' voetsporen - studie 31
Paulus' voetsporen - studie 31Paulus' voetsporen - studie 31
Paulus' voetsporen - studie 31
goedbericht
 

Viewers also liked (13)

Политический капитал оппозиционного политика
Политический капитал оппозиционного политикаПолитический капитал оппозиционного политика
Политический капитал оппозиционного политика
 
Slide 1
Slide 1Slide 1
Slide 1
 
Installing nagios core_from_source
Installing nagios core_from_sourceInstalling nagios core_from_source
Installing nagios core_from_source
 
Cellulair imuunrespons
Cellulair imuunresponsCellulair imuunrespons
Cellulair imuunrespons
 
Ingles
InglesIngles
Ingles
 
Tony kelly
Tony kellyTony kelly
Tony kelly
 
Securities and Exchange Commission Filings - Reynolds Week 2011
Securities and Exchange Commission Filings - Reynolds Week 2011Securities and Exchange Commission Filings - Reynolds Week 2011
Securities and Exchange Commission Filings - Reynolds Week 2011
 
Tabernakel1
Tabernakel1Tabernakel1
Tabernakel1
 
Calendario student card 2017
Calendario student card 2017Calendario student card 2017
Calendario student card 2017
 
Data envelopment analysis
Data envelopment analysisData envelopment analysis
Data envelopment analysis
 
Target audience guidance
Target audience guidanceTarget audience guidance
Target audience guidance
 
Reken maar 6
Reken maar 6Reken maar 6
Reken maar 6
 
Paulus' voetsporen - studie 31
Paulus' voetsporen - studie 31Paulus' voetsporen - studie 31
Paulus' voetsporen - studie 31
 

Similar to NY Prostate Cancer Conference - A. Vickers - Session 1: Traditional statistical methods for evaluating prediction models are uninformative: towards a decision analytic approach

screening for diseases.pptx . ...
screening for diseases.pptx .             ...screening for diseases.pptx .             ...
screening for diseases.pptx . ...
AkshayBadore2
 
Measuring clinical utility: uncertainty in Net Benefit
Measuring clinical utility: uncertainty in Net BenefitMeasuring clinical utility: uncertainty in Net Benefit
Measuring clinical utility: uncertainty in Net Benefit
Laure Wynants
 
NY Prostate Cancer Conference - A. Vickers - Session 8: Debate 2: Categorical...
NY Prostate Cancer Conference - A. Vickers - Session 8: Debate 2: Categorical...NY Prostate Cancer Conference - A. Vickers - Session 8: Debate 2: Categorical...
NY Prostate Cancer Conference - A. Vickers - Session 8: Debate 2: Categorical...European School of Oncology
 
screening-140217071714-phpapp02.pdf
screening-140217071714-phpapp02.pdfscreening-140217071714-phpapp02.pdf
screening-140217071714-phpapp02.pdf
SYEDZIYADFURQAN
 
Common statistical pitfalls & errors in biomedical research (a top-5 list)
Common statistical pitfalls & errors in biomedical research (a top-5 list)Common statistical pitfalls & errors in biomedical research (a top-5 list)
Common statistical pitfalls & errors in biomedical research (a top-5 list)
Evangelos Kritsotakis
 
Evidence based diagnosis
Evidence based diagnosisEvidence based diagnosis
Evidence based diagnosis
Hesham Al-Inany
 
Screening
ScreeningScreening
Evidence-based diagnosis
Evidence-based diagnosisEvidence-based diagnosis
Evidence-based diagnosisHesham Gaber
 
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...cambridgeWD
 
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...cambridgeWD
 
Karl Ulrich Petry - Colposcopic practice performance standards
Karl Ulrich Petry - Colposcopic practice performance standardsKarl Ulrich Petry - Colposcopic practice performance standards
Karl Ulrich Petry - Colposcopic practice performance standards
triumphbenelux
 
UAB Pulmonary board review study design and statistical principles
UAB Pulmonary board review study  design and statistical principles UAB Pulmonary board review study  design and statistical principles
UAB Pulmonary board review study design and statistical principles
Terry Shaneyfelt
 
Biostatistics in development of Medical Devices By T. Mudde - Clinquest (Qser...
Biostatistics in development of Medical Devices By T. Mudde - Clinquest (Qser...Biostatistics in development of Medical Devices By T. Mudde - Clinquest (Qser...
Biostatistics in development of Medical Devices By T. Mudde - Clinquest (Qser...qserveconference2013
 
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...European School of Oncology
 
Validity of a screening test
Validity of a screening testValidity of a screening test
Validity of a screening test
drkulrajat
 
NY Prostate Cancer Conference - M.W. Kattan - Debate 1: Do I need a nomogram ...
NY Prostate Cancer Conference - M.W. Kattan - Debate 1: Do I need a nomogram ...NY Prostate Cancer Conference - M.W. Kattan - Debate 1: Do I need a nomogram ...
NY Prostate Cancer Conference - M.W. Kattan - Debate 1: Do I need a nomogram ...European School of Oncology
 
Medical Statistics used in Oncology
Medical Statistics used in OncologyMedical Statistics used in Oncology
Medical Statistics used in Oncology
Namrata Das
 
Biostatistics
BiostatisticsBiostatistics
Biostatistics
Larry Baum
 

Similar to NY Prostate Cancer Conference - A. Vickers - Session 1: Traditional statistical methods for evaluating prediction models are uninformative: towards a decision analytic approach (20)

screening for diseases.pptx . ...
screening for diseases.pptx .             ...screening for diseases.pptx .             ...
screening for diseases.pptx . ...
 
Measuring clinical utility: uncertainty in Net Benefit
Measuring clinical utility: uncertainty in Net BenefitMeasuring clinical utility: uncertainty in Net Benefit
Measuring clinical utility: uncertainty in Net Benefit
 
NY Prostate Cancer Conference - A. Vickers - Session 8: Debate 2: Categorical...
NY Prostate Cancer Conference - A. Vickers - Session 8: Debate 2: Categorical...NY Prostate Cancer Conference - A. Vickers - Session 8: Debate 2: Categorical...
NY Prostate Cancer Conference - A. Vickers - Session 8: Debate 2: Categorical...
 
screening-140217071714-phpapp02.pdf
screening-140217071714-phpapp02.pdfscreening-140217071714-phpapp02.pdf
screening-140217071714-phpapp02.pdf
 
Common statistical pitfalls & errors in biomedical research (a top-5 list)
Common statistical pitfalls & errors in biomedical research (a top-5 list)Common statistical pitfalls & errors in biomedical research (a top-5 list)
Common statistical pitfalls & errors in biomedical research (a top-5 list)
 
Clinical epidemiology
Clinical epidemiologyClinical epidemiology
Clinical epidemiology
 
Evidence based diagnosis
Evidence based diagnosisEvidence based diagnosis
Evidence based diagnosis
 
Screening
ScreeningScreening
Screening
 
Evidence-based diagnosis
Evidence-based diagnosisEvidence-based diagnosis
Evidence-based diagnosis
 
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
 
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
 
Lund 2009
Lund 2009Lund 2009
Lund 2009
 
Karl Ulrich Petry - Colposcopic practice performance standards
Karl Ulrich Petry - Colposcopic practice performance standardsKarl Ulrich Petry - Colposcopic practice performance standards
Karl Ulrich Petry - Colposcopic practice performance standards
 
UAB Pulmonary board review study design and statistical principles
UAB Pulmonary board review study  design and statistical principles UAB Pulmonary board review study  design and statistical principles
UAB Pulmonary board review study design and statistical principles
 
Biostatistics in development of Medical Devices By T. Mudde - Clinquest (Qser...
Biostatistics in development of Medical Devices By T. Mudde - Clinquest (Qser...Biostatistics in development of Medical Devices By T. Mudde - Clinquest (Qser...
Biostatistics in development of Medical Devices By T. Mudde - Clinquest (Qser...
 
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
 
Validity of a screening test
Validity of a screening testValidity of a screening test
Validity of a screening test
 
NY Prostate Cancer Conference - M.W. Kattan - Debate 1: Do I need a nomogram ...
NY Prostate Cancer Conference - M.W. Kattan - Debate 1: Do I need a nomogram ...NY Prostate Cancer Conference - M.W. Kattan - Debate 1: Do I need a nomogram ...
NY Prostate Cancer Conference - M.W. Kattan - Debate 1: Do I need a nomogram ...
 
Medical Statistics used in Oncology
Medical Statistics used in OncologyMedical Statistics used in Oncology
Medical Statistics used in Oncology
 
Biostatistics
BiostatisticsBiostatistics
Biostatistics
 

More from European School of Oncology

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...European School of Oncology
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...European School of Oncology
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasEuropean School of Oncology
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasEuropean School of Oncology
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineEuropean School of Oncology
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...European School of Oncology
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artEuropean School of Oncology
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...European School of Oncology
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer European School of Oncology
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerEuropean School of Oncology
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artEuropean School of Oncology
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...European School of Oncology
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artEuropean School of Oncology
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...European School of Oncology
 

More from European School of Oncology (20)

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
W. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - GuidelinesW. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - Guidelines
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomas
 
H. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the artH. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the art
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
 
1 azim
1 azim1 azim
1 azim
 
H. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the artH. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the art
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccine
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the art
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
 
V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancer
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the art
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the art
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
 

Recently uploaded

Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdfSmart TV Buyer Insights Survey 2024 by 91mobiles.pdf
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf
91mobiles
 
Connector Corner: Automate dynamic content and events by pushing a button
Connector Corner: Automate dynamic content and events by pushing a buttonConnector Corner: Automate dynamic content and events by pushing a button
Connector Corner: Automate dynamic content and events by pushing a button
DianaGray10
 
Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...
Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...
Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...
Product School
 
De-mystifying Zero to One: Design Informed Techniques for Greenfield Innovati...
De-mystifying Zero to One: Design Informed Techniques for Greenfield Innovati...De-mystifying Zero to One: Design Informed Techniques for Greenfield Innovati...
De-mystifying Zero to One: Design Informed Techniques for Greenfield Innovati...
Product School
 
UiPath Test Automation using UiPath Test Suite series, part 4
UiPath Test Automation using UiPath Test Suite series, part 4UiPath Test Automation using UiPath Test Suite series, part 4
UiPath Test Automation using UiPath Test Suite series, part 4
DianaGray10
 
UiPath Test Automation using UiPath Test Suite series, part 3
UiPath Test Automation using UiPath Test Suite series, part 3UiPath Test Automation using UiPath Test Suite series, part 3
UiPath Test Automation using UiPath Test Suite series, part 3
DianaGray10
 
The Art of the Pitch: WordPress Relationships and Sales
The Art of the Pitch: WordPress Relationships and SalesThe Art of the Pitch: WordPress Relationships and Sales
The Art of the Pitch: WordPress Relationships and Sales
Laura Byrne
 
Monitoring Java Application Security with JDK Tools and JFR Events
Monitoring Java Application Security with JDK Tools and JFR EventsMonitoring Java Application Security with JDK Tools and JFR Events
Monitoring Java Application Security with JDK Tools and JFR Events
Ana-Maria Mihalceanu
 
Leading Change strategies and insights for effective change management pdf 1.pdf
Leading Change strategies and insights for effective change management pdf 1.pdfLeading Change strategies and insights for effective change management pdf 1.pdf
Leading Change strategies and insights for effective change management pdf 1.pdf
OnBoard
 
Designing Great Products: The Power of Design and Leadership by Chief Designe...
Designing Great Products: The Power of Design and Leadership by Chief Designe...Designing Great Products: The Power of Design and Leadership by Chief Designe...
Designing Great Products: The Power of Design and Leadership by Chief Designe...
Product School
 
FIDO Alliance Osaka Seminar: Passkeys at Amazon.pdf
FIDO Alliance Osaka Seminar: Passkeys at Amazon.pdfFIDO Alliance Osaka Seminar: Passkeys at Amazon.pdf
FIDO Alliance Osaka Seminar: Passkeys at Amazon.pdf
FIDO Alliance
 
Dev Dives: Train smarter, not harder – active learning and UiPath LLMs for do...
Dev Dives: Train smarter, not harder – active learning and UiPath LLMs for do...Dev Dives: Train smarter, not harder – active learning and UiPath LLMs for do...
Dev Dives: Train smarter, not harder – active learning and UiPath LLMs for do...
UiPathCommunity
 
Key Trends Shaping the Future of Infrastructure.pdf
Key Trends Shaping the Future of Infrastructure.pdfKey Trends Shaping the Future of Infrastructure.pdf
Key Trends Shaping the Future of Infrastructure.pdf
Cheryl Hung
 
Transcript: Selling digital books in 2024: Insights from industry leaders - T...
Transcript: Selling digital books in 2024: Insights from industry leaders - T...Transcript: Selling digital books in 2024: Insights from industry leaders - T...
Transcript: Selling digital books in 2024: Insights from industry leaders - T...
BookNet Canada
 
Assuring Contact Center Experiences for Your Customers With ThousandEyes
Assuring Contact Center Experiences for Your Customers With ThousandEyesAssuring Contact Center Experiences for Your Customers With ThousandEyes
Assuring Contact Center Experiences for Your Customers With ThousandEyes
ThousandEyes
 
From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...
From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...
From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...
Product School
 
Essentials of Automations: Optimizing FME Workflows with Parameters
Essentials of Automations: Optimizing FME Workflows with ParametersEssentials of Automations: Optimizing FME Workflows with Parameters
Essentials of Automations: Optimizing FME Workflows with Parameters
Safe Software
 
From Siloed Products to Connected Ecosystem: Building a Sustainable and Scala...
From Siloed Products to Connected Ecosystem: Building a Sustainable and Scala...From Siloed Products to Connected Ecosystem: Building a Sustainable and Scala...
From Siloed Products to Connected Ecosystem: Building a Sustainable and Scala...
Product School
 
PCI PIN Basics Webinar from the Controlcase Team
PCI PIN Basics Webinar from the Controlcase TeamPCI PIN Basics Webinar from the Controlcase Team
PCI PIN Basics Webinar from the Controlcase Team
ControlCase
 
GraphRAG is All You need? LLM & Knowledge Graph
GraphRAG is All You need? LLM & Knowledge GraphGraphRAG is All You need? LLM & Knowledge Graph
GraphRAG is All You need? LLM & Knowledge Graph
Guy Korland
 

Recently uploaded (20)

Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdfSmart TV Buyer Insights Survey 2024 by 91mobiles.pdf
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf
 
Connector Corner: Automate dynamic content and events by pushing a button
Connector Corner: Automate dynamic content and events by pushing a buttonConnector Corner: Automate dynamic content and events by pushing a button
Connector Corner: Automate dynamic content and events by pushing a button
 
Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...
Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...
Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...
 
De-mystifying Zero to One: Design Informed Techniques for Greenfield Innovati...
De-mystifying Zero to One: Design Informed Techniques for Greenfield Innovati...De-mystifying Zero to One: Design Informed Techniques for Greenfield Innovati...
De-mystifying Zero to One: Design Informed Techniques for Greenfield Innovati...
 
UiPath Test Automation using UiPath Test Suite series, part 4
UiPath Test Automation using UiPath Test Suite series, part 4UiPath Test Automation using UiPath Test Suite series, part 4
UiPath Test Automation using UiPath Test Suite series, part 4
 
UiPath Test Automation using UiPath Test Suite series, part 3
UiPath Test Automation using UiPath Test Suite series, part 3UiPath Test Automation using UiPath Test Suite series, part 3
UiPath Test Automation using UiPath Test Suite series, part 3
 
The Art of the Pitch: WordPress Relationships and Sales
The Art of the Pitch: WordPress Relationships and SalesThe Art of the Pitch: WordPress Relationships and Sales
The Art of the Pitch: WordPress Relationships and Sales
 
Monitoring Java Application Security with JDK Tools and JFR Events
Monitoring Java Application Security with JDK Tools and JFR EventsMonitoring Java Application Security with JDK Tools and JFR Events
Monitoring Java Application Security with JDK Tools and JFR Events
 
Leading Change strategies and insights for effective change management pdf 1.pdf
Leading Change strategies and insights for effective change management pdf 1.pdfLeading Change strategies and insights for effective change management pdf 1.pdf
Leading Change strategies and insights for effective change management pdf 1.pdf
 
Designing Great Products: The Power of Design and Leadership by Chief Designe...
Designing Great Products: The Power of Design and Leadership by Chief Designe...Designing Great Products: The Power of Design and Leadership by Chief Designe...
Designing Great Products: The Power of Design and Leadership by Chief Designe...
 
FIDO Alliance Osaka Seminar: Passkeys at Amazon.pdf
FIDO Alliance Osaka Seminar: Passkeys at Amazon.pdfFIDO Alliance Osaka Seminar: Passkeys at Amazon.pdf
FIDO Alliance Osaka Seminar: Passkeys at Amazon.pdf
 
Dev Dives: Train smarter, not harder – active learning and UiPath LLMs for do...
Dev Dives: Train smarter, not harder – active learning and UiPath LLMs for do...Dev Dives: Train smarter, not harder – active learning and UiPath LLMs for do...
Dev Dives: Train smarter, not harder – active learning and UiPath LLMs for do...
 
Key Trends Shaping the Future of Infrastructure.pdf
Key Trends Shaping the Future of Infrastructure.pdfKey Trends Shaping the Future of Infrastructure.pdf
Key Trends Shaping the Future of Infrastructure.pdf
 
Transcript: Selling digital books in 2024: Insights from industry leaders - T...
Transcript: Selling digital books in 2024: Insights from industry leaders - T...Transcript: Selling digital books in 2024: Insights from industry leaders - T...
Transcript: Selling digital books in 2024: Insights from industry leaders - T...
 
Assuring Contact Center Experiences for Your Customers With ThousandEyes
Assuring Contact Center Experiences for Your Customers With ThousandEyesAssuring Contact Center Experiences for Your Customers With ThousandEyes
Assuring Contact Center Experiences for Your Customers With ThousandEyes
 
From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...
From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...
From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...
 
Essentials of Automations: Optimizing FME Workflows with Parameters
Essentials of Automations: Optimizing FME Workflows with ParametersEssentials of Automations: Optimizing FME Workflows with Parameters
Essentials of Automations: Optimizing FME Workflows with Parameters
 
From Siloed Products to Connected Ecosystem: Building a Sustainable and Scala...
From Siloed Products to Connected Ecosystem: Building a Sustainable and Scala...From Siloed Products to Connected Ecosystem: Building a Sustainable and Scala...
From Siloed Products to Connected Ecosystem: Building a Sustainable and Scala...
 
PCI PIN Basics Webinar from the Controlcase Team
PCI PIN Basics Webinar from the Controlcase TeamPCI PIN Basics Webinar from the Controlcase Team
PCI PIN Basics Webinar from the Controlcase Team
 
GraphRAG is All You need? LLM & Knowledge Graph
GraphRAG is All You need? LLM & Knowledge GraphGraphRAG is All You need? LLM & Knowledge Graph
GraphRAG is All You need? LLM & Knowledge Graph
 

NY Prostate Cancer Conference - A. Vickers - Session 1: Traditional statistical methods for evaluating prediction models are uninformative: towards a decision analytic approach

  • 1.
  • 2. The Kattan challenge A clinician comes to you with two models (or tests) and wants to know which to use. What statistical method do you use to help answer the clinician?
  • 3. Traditional biostatistical metrics   Sensitivity Specificity PPV NPV LR+ LR- AUC (Youden) Brier (mean squared error) % Free PSA < 20% 91% 40% 35% 92% 1.52 0.23 0.65 0.47 hK2 > 75 pg / ml 51% 78% 45% 82% 2.32 0.63 0.64 0.29
  • 4.
  • 5.
  • 6. Prostate cancer High risk (10%) Low Risk (90%)
  • 7. Prostate cancer Use of the model to determine treatment would avoid 47 unnecessary treatments at the expense of failing to treat 45 patients who do require treatment.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21. Application to models with a continuous endpoint 1. Select a p t 2. Positive test defined as 3. Calculate “Clinical Net Benefit” as:
  • 22. Kallikrein panel: weight false positives by 20% ÷ (1 – 20%) Cancers found Unecessary Biopsies Net benefit Biopsy all men with elevated PSA 277 723 277 - 723 ÷ 4 96.25 Biopsy if risk ≥ 20% on panel 211 276 211 - 276 ÷ 4 142
  • 23.
  • 24.
  • 25. Decision curve analysis 4. Vary p t over an appropriate range Vickers & Elkin Med Decis Making 2006;26:565–574 1. Select a p t 2. Positive test defined as 3. Calculate “Clinical Net Benefit” as:
  • 27.
  • 29.  
  • 30.  
  • 31. Statistical analysis vs. decision analysis Traditional statistical analysis Traditional decision analysis Mathematics Simple Can be complex Additional data Not required Patient preferences, costs or effectiveness Endpoints Binary or continuous Continuous endpoints problematic Assess clinical value? No Yes
  • 32. Statistical analysis vs. decision analysis Traditional statistical analysis Traditional decision analysis Decision curve analysis Mathematics Simple Can be complex Simple Additional data Not required Patient preferences, costs or effectiveness Informal, general estimates Endpoints Binary or continuous Continuous endpoints problematic Binary or continuous Assess clinical value? No Yes Yes
  • 33.